As iNKT Moves Forward, Cell Therapy Competition Shifts from Efficacy to Manufacturability

The recent collaboration between MiNK Therapeutics and C-Further to advance a PRAME-targeted iNKT cell therapy for pediatric cancers reflects more than a single pipeline update. As noted in recent industry coverage by OncoDaily, it signals a broader structural shift in the cell therapy landscape.

Over the past decade, CAR-T therapies have defined the field, particularly in hematologic malignancies. However, as clinical efficacy and commercialization pathways become clearer, innovation is expanding into alternative immune cell types such as NK and iNKT cells. These emerging modalities are not simply incremental additions; they represent a transition toward a multi-platform ecosystem, each with distinct biological and translational characteristics.

 Photo by Marvin Radke on Unsplash

Among them, iNKT cells are gaining attention due to their hybrid immune properties and their potential advantages in safety and solid tumor applications. At the same time, targets such as PRAME are reinforcing the trend toward broader applicability across tumor types.

Yet, the emergence of new modalities also introduces new challenges. The field is moving beyond proof-of-concept toward a more complex phase where success depends not only on efficacy, but also on manufacturability. Questions around scalability, batch consistency, and process robustness are becoming central to development strategies.

This shift is redefining competition. While it may appear as a race between different cell types, the underlying differentiator is increasingly manufacturing capability. Regardless of modality, the ability to translate biological complexity into reproducible, scalable, and regulatory-compliant processes will ultimately determine long-term success.

Photo by National Cancer Institute on Unsplash

Consequently, foundational platforms—such as standardized expansion systems and engineered cellular support frameworks—are emerging as critical enablers. Particularly for NK and iNKT therapies, where ex vivo expansion is essential, these platforms are no longer optional optimizations but core infrastructure.

In this context, the collaboration between MiNK Therapeutics and C-Further highlights a key industry transition: from a phase driven primarily by scientific discovery to one increasingly defined by engineering and production excellence. As the number of therapeutic approaches continues to grow, the decisive factor will not only be which therapy works, but which can be consistently and efficiently delivered at scale.

Source: OncoDaily Weekly Report, March 2026